Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL

Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma

Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection

Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers

Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery

Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed

Oncology Times - OncTimes Talk

Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL

Download our free app to listen on your phone